ARCA

After pharmacogenetic analysis in a Phase II melanoma study for tremelimumab failed to yield any clinically meaningful gene-response markers, Pfizer inked a codevelopment deal with Debiopharm handing over Phase III development of the drug with a protein marker linked to response. But commercialization rights still belong to Pfizer.

Patent number 7,678,824, entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting," provides market exclusivity to ARCA for its approach to treating patients with heart failure.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.